Growing Grassroots Support for the Rare Disease Community in Romania

NoRo pilots the country’s first and only patient-run reference center for rare diseases

In 2007, Dorica Dan, the mother of a child with the rare disease Prader Willi Syndrome, envisioned the first and only patient-run reference center for rare diseases in Europe. It would help patients and families with the decisions and therapies that are needed after receiving their diagnosis.

Skis, Skincare, and More: Making Better Products With Algae

Materials innovation company Checkerspot is using microalgae to create a sustainable alternative to petroleum

Molecular biologist Scott Franklin has spent the last 25 years in awe of the secret properties of microalgae—what he calls “the mother of all higher plants.” While many people consider it an environmental scourge—certain species have the power to proliferate into a toxic bloom within hours—microalgae is, for Franklin, a wondrous source of triglyceride oils and fatty acids. “There are thousands of strains of microalgae everywhere, but you don’t see them,” he says. “There’s a huge diversity out there.”

“The World Expands”: Celebrating Rare Disease Day in Japan

Through an organization called ASrid, patient families find connection and hope

Ahead of Rare Disease Day, Illumina is recognizing four rare disease patient organizations around the world. ASrid is the third in our series this month.

The kids in Kanade Kawagoe’s elementary school class were excited to see a Polaroid camera for the first time. “The children, who are used to being photographed with their cell phone cameras, waited with sparkling eyes for the photos to come out of the camera,” says Naomi Kawagoe, Kanade’s mother. “The sight of these children was awe-inspiring.” The Kawagoes were photographing a day in the life of rare disease.

From Patents to Patients: Meet the Women Making a Difference at Illumina

On National Inventors Day, two employees talk about getting “hooked” on sequencing and the importance of being wrong (sometimes)

As a global leader in DNA sequencing and array-based technologies, Illumina is continuously striving to improve human health by unlocking the power of the genome. That means focusing on innovation—constant innovation. In 2021, Illumina employees filed a record 171 new patent applications—a 69 percent increase over the previous year.

African Coronavirus Surveillance Network Provides Early Warning for World

Multimedia with summary

As part of the support, Illumina pledged $20 million over four years to help strengthen sequencing technology for 20 African countries. This in-kind donation includes next-generation sequencing platforms, reagents and training support.

Illumina to Support Neuro Genomics Project at McGill University


Today, the Montreal Neurological Institute-Hospital at McGill University (The Neuro) announced a new research collaboration with Illumina, along with Takeda Development Center Americas, Inc., and pharmaceutical powerhouse Roche. Driven by the power of Illumina’s WGS capability, the partnership will create a powerful drug discovery platform for neurological conditions such as Parkinson’s disease and REM sleep behavior disorders.

Patient Success Story: Beating Stage IV Lung Cancer

AJ Patel had six months to live. Eight years later, he tells us how biomarker testing changed everything.

Eight years ago, AJ Patel was diagnosed with advanced lung cancer. The Southern California resident and father of three had tumor masses in both lungs. AJ’s doctor told him that if he didn’t do anything, he would have just six months to live. But fortunately, AJ met a physician who recommended he ask about biomarker testing, an approach that uses next-generation sequencing to determine an individual’s cancer-causing genes and other markers.

Illumina Partners With Centers Across France to Advance a Precision Medicine Approach for Patients With Late-Stage Cancer

Joint study will assess clinical value of comprehensive genomic profiling (CGP) on cancer therapy options in patients with advanced disease
Press Release

SAN DIEGO, February 7, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ:ILMN), today announced an agreement with the Jean Perrin Center at the Clermont-Ferrand University Hospital in France to assess the clinical value of comprehensive genomic profiling (CGP) in cancer therapy options in patients with late-stage disease compared to use of current standard of care, including small panel tests.

Illumina Earns Gold Class in the S&P Global's 2022 Sustainability Yearbook

Multimedia with summary

Our ESG commitments and actions support our goal for a global health transformation.

We’re excited to earn the highest distinction of a Gold Class in the S&P Global's 2022 Sustainability Yearbook.

We also were given the distinction of an Industry Mover, which recognizes companies that demonstrated the strongest year-over-year score improvement.


Subscribe to NASDAQ: ILMN